Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
Phase 1
Not yet recruiting
- Conditions
- High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 660
- Registration Number
- NCT06099990
Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
Phase 1
Completed
- Conditions
- Malignant Tumor
- Interventions
- Drug: SHR2554 tablet dosing
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06093945
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Phase 3
Not yet recruiting
- Conditions
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06091748
A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06086912
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide
Phase 1
Completed
- Conditions
- Diabetes in Adults
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06083116
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Adult Patients With Chronic Primary ITPAdult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT06062680
Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
Phase 1
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: HRS-9815 injection
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06062355
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Phase 3
Recruiting
- Conditions
- HER2-PositiveRecurrent or Metastatic Breast Cancer
- Interventions
- Drug: SHR-A1811 Injection ； Pertuzumab InjectionDrug: SHR-A1811 Injection
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 864
- Registration Number
- NCT06057610
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Trial of HRF2105 Patch in Relieving Pain of Osteoarthritis
Phase 2
Not yet recruiting
- Conditions
- Analgesia and Anti-inflammatory of Osteoarthritis
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06047483
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: HRG2005 inhalationDrug: Placebo to match HRG2005 inhalation
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06035393
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath